The drug companies were back in 2014 for another round aimed at influencing public policy, directing money most squarely at the Democratic leadership in the Legislature, but not the governor, who aims to give more authority to CCOs to rein in the purchase of high-cost brand name pharmaceuticals.
This story is part three in a three-part series on healthcare-related Oregon state campaign finance contributions.
February 12, 2015
